DefinitionThis section has been translated automatically.
Antileukotriene(leukotriene receptor antagonist).
Pharmacodynamics (Effect)This section has been translated automatically.
Montelukast binds to the cysteinyl leukotriene 1 receptor, thus preventing the binding of leukotriene to this receptor, interrupting the leukotriene-mediated inflammatory reaction (the binding of leukotriene to the cysteinyl leukotriene 1 receptor leads to edema formation, damage to the bronchial epithelium and bronchoconstriction, resulting in narrowing of the airways due to bronchial muscle contraction).
You might also be interested in
IndicationThis section has been translated automatically.
- Supplementary therapy for mild to moderate chronic bronchial asthma that cannot be adequately treated with inhaled corticosteroids or adequately controlled by the use of short-acting beta-sympathomimetics as needed. Prophylaxis of exercise-induced asthma (asthma during physical exercise).
Remember! Not approved for the treatment of acute asthma attacks.
- Off-label use: In case studies also successful in the treatment of chronic urticaria.
Pregnancy/nursing periodThis section has been translated automatically.
Strict benefit-risk assessment (insufficient data available)!
Dosage and method of useThis section has been translated automatically.
- Adults: 1 time a day 10 mg p.o. before bedtime.
- Children/teenagers 6-14 LJ: once/day 5 mg p.o. before bedtime.
- Children 2-5 LJ: once/day 4 mg p.o. before bedtime.
Undesirable effectsThis section has been translated automatically.
- In young children: Occasionally: Diarhoea, hyperactivity, asthma, skin changes like dermatitis, thirst.
- In adolescents/adults: headache, stomach ache.
InteractionsThis section has been translated automatically.
Drugs that induce increased activity of cytochrome P450 3A4; in particular phenytoin, rifampicin, phenobarbital, cause a reduction in the bioavailability of montelukast.
PreparationsThis section has been translated automatically.
Singulair®
Note(s)This section has been translated automatically.
Effect begins as early as 1 day after the start of therapy; therapy should be continued if there are no symptoms and if the condition worsens.
Prof. Dr. med. Peter Altmeyer